Last updated on August 2019

A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis


Brief description of study

Primary Objective:

- To determine the efficacy of SAR442168 in reducing the number of new brain lesions reported in Magnetic Resonance Imaging (MRI)

Secondary Objectives:

- To evaluate the efficacy of SAR442168 on clinical symptoms and imaging measures

- To evaluate the safety and tolerability of SAR442168

 

Clinical Study Identifier: TX227903

Find a site near you

Start Over